

## INFORMATION DISCLOSURE STATEMENT

Applicant: De Sauvage et al.

App. No : 08/793,653

Filed : February 27, 1997

For : OB PROTEIN IMMUNOGLOBULIN  
CHIMERAS

Examiner : Zachary C. Howard

Art Unit : 1646

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 22, 2005

(Date)

Eli A. Loots, Reg. No. 54,715

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 12 references to be considered by the Examiner. Also enclosed are 12 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing date of a Notice of Allowance.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(2)

I hereby certify that no item of information contained in this Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months days/months prior to the filing of this Information Disclosure Statement.

**Appl. No.** : 08/793,653  
**Filed** : February 27, 1997

**Docket No.** GENENT.052CP2  
**Customer No.** 20,995

Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 11/02/05

By: 

Eli A. Loots  
Registration No. 54,715  
Attorney of Record  
Customer No. 20,995  
(415) 954-4114

2083833  
112205

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Multiple sheets used when necessary) SHEET 1 OF 1	Application No.	08/793,653	
	Filing Date	February 27, 1997	
	First Named Inventor	Frederic De Sauvage	
	Art Unit	1646	
	Examiner	Zachary C. Howard	
		Attorney Docket No.	GENENT.052CP2

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	1	BREWERTON et al. "Reduced plasma leptin concentrations in bulimia nervosa," Psychoneuroendocrinology, 2000, 25:649-658	
	2	CAMPFIELD et al. "Strategies and Potential Molecular Targets for Obesity Treatment", Science, May 1998, 280:1383-1387	
	3	CHEN et al. "Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in <i>db/db</i> Mice," Cell, Feb 1996, 84:491-495	
	4	COLEMAN, D.L. "Obese and Diabetes: Two Mutant Genes Causing Diabetes-Obesity Syndromes in Mice," Diabetologia, 1978, 14:141-148	
	5	FAROOQI et al. "Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency," New England J Med, Sept 1999, 341(12):879-884	
	6	HANAKI et al. "Leptin Before and After Insulin Therapy in Children with New-Onset Type 1 Diabetes," J Clin Endo & Metab, 1999, 84(5):1524-1526	
	7	HEYMSFIELD et al. "Recombinant Leptin for Weight Loss in Obese and Lean Adults," JAMA, Oct 1999, 282(16):1568-1575	
	8	HUKSHORN et al. "Weekly Subcutaneous Pegylated Recombinant Native Human Leptin (PEG-OB) Administration in Obese Men," J Clin Endo & Metab, 2000, 85(11):4003-4008	
	9	JIMERSON et al. "Decreased Serum Leptin in Bulimia Nervosa", J Clin Endo & Metab, 2000, 85(12):4511-4514	
	10	REDDY et al. "Immunohistochemical demonstration of leptin in pancreatic islets of non-obese diabetic and CD-1 mice: Co-localization in glucagon cells and its attenuation at the onset of diabetes," J Mol Histology, 2004, 35:511-519	
	11	ROSENBAUM et al. "Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones," J Clin Endo & Metab, May 2002, 87(5):2391-2394	
	12	TAYLOR et al. "Impact of Binge Eating on Metabolic and Leptin Dynamics in Normal Young Women," J Clin Endo & Metab, 1999, 84(2):428-434	

2083452//112205

Examiner Signature	Date Considered
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.